Stopped (Investigation of ACE-083 for use in patients with CMT is being discontinued as it did not achieve functional secondary endpoints in the A083-03 trial.
Conditions
Charcot-Marie-Tooth Disease
Interventions
DRUG: ACE-083
DRUG: Placebo
Sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA